Novartis Pluvicto Delays Progression to End-Stage Prostate Cancer
PSMAddition data show that Novartis Pluvicto delays progression to end-stage prostate cancer.
Novartis is a leading medicines company that aims to improve and extend people's lives through innovative treatments.
- The company's medicines reach 296 million people worldwide.
- Novartis provides resources for patients, healthcare professionals, and societies to empower them in the face of serious disease.
As stated by the company,
every day, we work to reimagine medicine to improve and extend people’s lives.
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Author's summary: Novartis Pluvicto delays prostate cancer progression.
More News
- Ectoplasmic – A Spiritual Post Frieze London 2025 - Sophie Parkin
- DraftKings Sunday Showdown: Week 7
- I use these 5 Windows troubleshooting tools to avoid paying for repairs
- The study that estimates the numbers of Russian dead in Ukraine at 219,000
- Trump posts AI video of himself in a jet dumping brown liquid on 'No Kings' protests
- The study that estimates the numbers of Russian dead in Ukraine at 219,000
- Pattaya residents lose faith in road repairs as maintenance leaves more damage than before - Pattaya Mail
- Global diplomatic impact of Budapest’s hosting Putin-Trump summit
- Redistricting Task Force grapples with Vermont's 'uniqueness'